BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative Employers
  Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Shire Pharmaceuticals 

725 Chesterbrook Boulevard

Wayne  Pennsylvania  19087-5637  U.S.A.
Phone: 484-595-8800 Fax: 484-595-8900


SEARCH JOBS


Founded in 1986, Shire is a fast-growing global specialty biopharmaceutical company with 2011 revenues of more than $4 billion and more than 5,000 employees worldwide. Working to enable those with life-altering conditions to lead better lives, we have a presence in 29 countries and several treatments available in nearly 50 countries. Our Brave culture encourages a challenge to the status quo, collaboration across cultures and geographic boundaries, the pursuit of innovation, and a firm focus on responsibility across everything we do.

Our operation is structured across three businesses – Human Genetic Therapies, Regenerative Medicine, and Specialty Pharmaceuticals – that are each supported by various corporate functions. With a major presence in Massachusetts, our Human Genetic Therapies team specializes in researching, developing, and commercializing therapies for the treatment of rare genetic diseases. Shire’s Specialty Pharmaceuticals team, with major operations in Pennsylvania, is made up currently of three business units – Attention Deficit Hyperactivity Disorder, Gastrointestinal diseases, and Emerging Products. This team also oversees many other marketed medicines approved to help people around the world. Based in California, our Regenerative Medicine business is focused on treatments that assist in restoring damaged tissue and supports the body’s natural healing process.

With international hub offices in the United Kingdom, Switzerland and Brazil, our Shire team is structured for strategic geographic expansion based on business milestones and opportunities.

By encouraging a Brave and responsible approach to all we do, Shire has evolved through strategic acquisitions into a unique, nimble organization that is able to act quickly and take advantage of business opportunities as they arise. Working as a team, our employees are motivated every day to achieve our purpose of enabling people with life-altering conditions to lead better lives.

We are always looking for talented people to join the Shire team. To learn more about Shire, visit www.shire.com. For more information on career opportunities with Shire, please visit: www.TimeToBeBrave.com.

Shire. To be as brave as the people we help.


 Key Statistics


Email:
Ownership: Public

Web Site: Shire Pharmaceuticals
Employees: 336
Symbol: SHPG
 



Industry
Pharmaceutical






 Company News
Shire plc Wins Patent Trial Against Watson Pharmaceuticals, Inc. (WPI) Concerning LIALDA® 5/9/2013 10:40:49 AM    More...
AGA Research Foundation Receives $200K Gift From Shire Pharmaceuticals (SHPG) 4/24/2013 9:41:16 AM    More...
Shire plc Launches Report that Quantifies the Health, Psycho-social and Economic Impact of Rare Diseases 4/9/2013 10:04:00 AM    More...
IMPAX Laboratories, Inc. (IPXL) Settles All Adderall XR Litigation With Shire Pharmaceuticals (SHPG) 2/8/2013 7:43:38 AM    More...
Shire plc Leads New Initiative to Reveal Challenges Facing Rare Disease Community 11/19/2012 9:37:38 AM    More...
Shire Pharmaceuticals (SHPG) Announces Third Annual Scholarship Program for Individuals With ADHD 11/6/2012 9:53:36 AM    More...
Shire Pharmaceuticals (SHPG) Hunts More Deals Amid Reawakening Interest in Stem Cell R&D 10/29/2012 7:06:19 AM    More...
Shire Pharmaceuticals (SHPG) Release: International Study Reveals Disconnect Between Patients and Healthcare Professionals (HCPS) Over Symptom Burden in Ulcerative Colitis (UC) 10/22/2012 10:07:49 AM    More...
Albany Molecular Research, Inc. (AMRI) (AMRI) Announces Five-Year Extension of API Supply Agreement With Shire 10/19/2012 7:28:32 AM    More...
Shire Pharmaceuticals (SHPGY) Announces FDA Acceptance of Filing for Review of the Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) sNDA for Maintenance Treatment in Children and Adolescents With ADHD European Medicines Agency 9/12/2012 10:16:24 AM    More...
12345678910...